Advertisement
Home »

Adding Chemotherapy to EGFR TKI Does Not Improve Overall Survival in Advanced NSCLC

Jun 12, 2023

REFERENCES & ADDITIONAL READING

Hosomi Y, et al. J Clin Oncol. 2020;38:115–123.

Kanda S, et al. A phase III study comparing EGFR-TKI monotherapy and EGFR-TKI with inserted cisplatin plus pemetrexed as a first-line treatment in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation: JCOG1404/WJOG8214L. Abstract LBA9009. ASCO Annual Meeting 2023, 2–6 June, Chicago.

Norronha V, et al. J Clin Oncol. 2020;38:124–136.

Ramalingam SS, et al. N Engl J Med. 2020;382:41–50.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement